Calamos Wealth Management LLC Acquires 872 Shares of Boston Scientific Co. (NYSE:BSX)

Calamos Wealth Management LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 155,432 shares of the medical equipment provider’s stock after purchasing an additional 872 shares during the period. Calamos Wealth Management LLC’s holdings in Boston Scientific were worth $13,883,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BSX. Values First Advisors Inc. acquired a new position in shares of Boston Scientific in the 3rd quarter valued at $28,000. Dunhill Financial LLC raised its stake in Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares in the last quarter. Global Wealth Strategies & Associates raised its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new position in shares of Boston Scientific in the third quarter worth approximately $30,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on BSX. Truist Financial lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. BTIG Research lifted their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James increased their target price on Boston Scientific from $101.00 to $119.00 and gave the stock a “strong-buy” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Friday, January 10th. Finally, Stifel Nicolaus boosted their price objective on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $100.39.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Boston Scientific stock opened at $103.11 on Tuesday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $151.97 billion, a P/E ratio of 85.22, a PEG ratio of 2.68 and a beta of 0.80. The stock has a fifty day moving average price of $93.47 and a 200 day moving average price of $86.33. Boston Scientific Co. has a 52 week low of $64.08 and a 52 week high of $104.25.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.